Eplerenone in heart failure Review article
Article Sidebar
Main Article Content
Abstract
Eplerenone, a selective mineralocorticoid receptor antagonist, plays a crucial role in the treatment of patients with heart failure with reduced ejection fraction. Its use reduces the risk of hospitalization and mortality in this patient group. Consequently, according to the guidelines of the European Society of Cardiology, mineralocorticoid receptor antagonist therapy is recommended as a Class I treatment for patients with heart failure with reduced ejection fraction, as well as for those who have experienced a myocardial infarction with a left ventricular ejection fraction ≤40% and coexisting heart failure or diabetes. An important advantage of eplerenone is its antifibrotic effect, which may help reduce the risk of arrhythmias, including atrial fibrillation. Additionally, due to its greater selectivity for mineralocorticoid receptors, eplerenone is associated with a lower risk of adverse effects compared to spironolactone.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Pitt B, Gheorghiade M, Zannad F et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction ≤30%. Eur J Heart Fail. 2006; 8(3): 295-301.
3. Naser N, Durak-Nalbantić A, Šabanović-Bajramović N et al. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure – HFrEF. Med Arch. 2023; 77: 105-11.
4. Adhikari A, Tadigotla C, Gaddam AR et al. Abstract 4141749: Eplerenone: The New Standard in Heart Failure Management-Insights Into Improved Ejection Fraction and Reduced Mortality Compared to Spironolactone: A Systematic Review And Meta Analysis. Circulation. 2024; 150(Suppl. 1): A4141749-A.
5. Asakura M, Ito S, Yamada T et al. Efficacy and Safety of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J Cardio Pharmacother. 2020; 8(2): 108-17.
6. Eschalier R, McMurray JJ, Swedberg K et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol. 2013; 62(17): 1585-93.
7. Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005; 45(11): 1832-9.
8. Calò L, Martino A, Sciarra L et al. Upstream effect for atrial fibrillation: still a dilemma? Pacing Clin Electrophysiol. 2011; 34(1): 111-28.
9. Swedberg K, Zannad F, McMurray JJ et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012; 59(18): 1598-603.
10. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021; 42(36): 3599-726.
11. Byrne RA, Rossello X, Coughlan JJ et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023; 44(38): 3720-826.
12. Lund LH, James S, DeVore AD et al. The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design. Eur J Heart Fail. 2024; 26(11): 2453-63.